Affinage

Showing ALX1 — CART1 is a alias.

ALX1

ALX homeobox protein 1 · UniProt Q15699

Length
326 aa
Mass
37.0 kDa
Annotated
2026-06-09
26 papers in source corpus 12 papers cited in narrative 12 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ALX1 is a paired-type homeodomain transcription factor that operates as a context-dependent transcriptional regulator at the top of gene regulatory networks governing skeletogenesis and craniofacial/ocular development (PMID:12756175, PMID:31331943, PMID:35127681). In sea urchin embryos it specifies the skeletogenic micromere lineage downstream of a beta-catenin/Pmar1-HesC double-negative gate, is initially driven by Ets1 and then maintained through auto-regulation that activates at moderate levels and represses at high levels via dimerization (PMID:12756175, PMID:21723273). Genome-wide ChIP-seq established that Alx1 directly drives terminal biomineralization effectors and the intermediate transcription factors of the skeletogenic network, binding both palindromic sites and TAAT half-sites; a unique exonization-derived D2 domain shapes its DNA-binding behavior, including dimeric assembly on redundant half-sites within target cis-regulatory modules (PMID:31331943, PMID:34157281). In mammalian development ALX1 is expressed in frontonasal neural crest and cranial mesoderm, where it is required for cranial neural crest cell migration, frontonasal mesenchyme identity (maintaining Pax7 and suppressing Lhx6/Lhx8), periocular mesenchyme survival, optic cup formation, and extraocular muscle myogenesis upstream of the core myogenic regulatory network (PMID:23059813, PMID:35127681, PMID:41010016, PMID:41670220). ALX1 is itself a direct transcriptional target of retinoic acid signaling through an upstream RARE, and is positioned downstream of a Pbx1-Emx2 heterodimer in skeletal patterning (PMID:20627960, PMID:41010016). A pathogenic homeodomain missense variant (p.L165F) impairs neural crest migration and increases apoptosis through dysregulated BMP signaling (PMID:32914578). In ovarian cancer cells ALX1 promotes epithelial-to-mesenchymal transition by transcriptionally upregulating SNAI1/Snail (PMID:23288509).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2003 High

    Established Alx1 as an essential upstream regulator of skeletogenic fate, answering how the micromere lineage is committed to biomineralization and EMT.

    Evidence Morpholino knockdown and epistasis in sea urchin embryos placing Alx1 downstream of beta-catenin/Pmar1

    PMID:12756175

    Open questions at the time
    • Direct downstream target genes not yet identified
    • DNA-binding specificity not defined
  2. 2010 High

    Identified upstream genetic inputs into Alx1, showing how a Pbx1-Emx2 heterodimer activates Alx1 in mammalian skeletal patterning.

    Evidence In vivo ChIP, heterodimer DNA-binding assay, and compound mutant epistasis in mouse embryos (scapula development)

    PMID:20627960

    Open questions at the time
    • Whether this regulation extends beyond scapula
    • Direct Alx1 targets in this context not defined
  3. 2011 High

    Dissected the cis-regulatory logic controlling alx1, explaining its rising-then-falling expression through Ets1 initiation, auto-activation, and dimerization-dependent auto-repression within a double-negative gate.

    Evidence Cis-regulatory reporter assays, binding-site mutagenesis, and synthetic overexpression in sea urchin

    PMID:21723273

    Open questions at the time
    • Structural basis of dimerization-dependent repression not resolved
    • Direct effector targets not yet mapped genome-wide
  4. 2012 Medium

    Defined a vertebrate developmental role, showing Alx1 is specifically required for cranial neural crest migration into the frontonasal primordia.

    Evidence Morpholino knockdown with foxd3/sox10 readouts and paralog specificity comparison in zebrafish

    PMID:23059813

    Open questions at the time
    • Direct transcriptional targets driving migration unknown
    • Morpholino-based, lacking genetic mutant confirmation at this stage
  5. 2013 Medium

    Extended ALX1 function to disease, showing it drives EMT in ovarian cancer cells by transcriptionally upregulating SNAI1.

    Evidence siRNA knockdown, overexpression, Snail-knockdown rescue, and invasion assays in ovarian cancer cells

    PMID:23288509

    Open questions at the time
    • Direct binding to SNAI1 promoter not demonstrated
    • Single lab, no in vivo tumor validation
  6. 2019 High

    Resolved the direct genomic targets of Alx1, demonstrating it directly activates terminal differentiation genes and intermediate transcription factors and binds both palindromic and half-sites in vivo.

    Evidence Genome-wide ChIP-seq with GFP reporter validation of 18 active CRMs and binding-site mutagenesis in sea urchin

    PMID:31331943

    Open questions at the time
    • Cofactors at half-sites versus palindromes not identified
    • Quantitative contribution of individual targets not parsed
  7. 2020 High

    Provided mechanistic insight into ALX1 disease pathology, linking a homeodomain missense variant to neural crest apoptosis and migration failure via altered BMP signaling.

    Evidence Patient iPSC-derived neural crest, zebrafish lineage tracing, and BMP2/BMP9 rescue experiments

    PMID:32914578

    Open questions at the time
    • Direct transcriptional link between ALX1 and BMP genes not established
    • Whether L165F is loss- or altered-function not fully resolved
  8. 2022 High

    Mapped the mammalian developmental requirements of ALX1, showing it maintains frontonasal mesenchyme identity and periocular mesenchyme survival with partial ALX4 redundancy.

    Evidence CRISPR/Cas9 knockout mice with marker analysis (Pitx2, Lmxb1, Pax7, Lhx6/Lhx8) and apoptosis assays

    PMID:35127681

    Open questions at the time
    • Direct ALX1 targets among the affected markers not defined
    • Mechanism of ALX4 complementation unknown
  9. 2022 Low

    Suggested an osteogenic role, with ALX1 activating a lncRNA (AC132217.4)-IGF2-AKT axis controlling osteoblast maturation.

    Evidence Promoter/TF analysis, gain/loss-of-function, RNA pulldown, and AKT phosphorylation assays in BMSCs

    PMID:35639207

    Open questions at the time
    • ALX1 direct binding to the lncRNA promoter described briefly without detailed mechanistic dissection
    • Single lab, one layer of a complex mechanism
  10. 2025 High

    Positioned ALX1 within retinoic acid signaling and ocular morphogenesis, showing it is a direct RA target required for optic cup formation.

    Evidence H3K27ac ChIP-seq, RNA-seq, RARE identification, and CRISPR/Cas9 knockout in mice

    PMID:41010016

    Open questions at the time
    • Direct ALX1 targets driving perioptic mesenchyme migration not identified
    • RARE functional requirement not tested by deletion
  11. 2026 High

    Revealed an unexpected cranial mesoderm role, showing ALX1 is required upstream of the core myogenic network for extraocular muscle formation.

    Evidence Conditional/temporally induced CRISPR knockout with myogenic marker and apoptosis analysis in mice

    PMID:41670220

    Open questions at the time
    • Direct myogenic target genes of ALX1 not defined
    • How ALX1 acts in both neural crest and mesoderm lineages mechanistically unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ALX1's distinct DNA-binding modes (palindrome versus half-site, dimerization, D2 domain) are deployed to select context-specific target sets across skeletogenic, craniofacial, ocular, myogenic, and cancer programs remains unresolved.
  • Cofactor partners directing context-specific binding unknown
  • No structural model of ALX1-DNA or ALX1 dimer complexes
  • Direct mammalian target genes largely uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 3
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-1266738 Developmental Biology 5 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1643685 Disease 2
Partners
EMX2ETS1PBX1

Evidence

Reading pass · 12 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Alx1 is a homeodomain transcription factor expressed exclusively in the large micromere lineage of sea urchin embryos, where it is essential for skeletogenic fate specification. Morpholino knockdown demonstrated it controls downstream genes required for epithelial-mesenchymal transition and biomineralization. Its expression is regulated cell-autonomously through beta-catenin and its downstream effector Pmar1. Morpholino knockdown, in situ hybridization, epistasis analysis Development High 12756175
2011 Cis-regulatory analysis of the alx1 locus demonstrated that Ets1 is the initial driver of alx1 expression, and then Alx1 itself plus Ets1 maintain expression. The Alx1 protein performs auto-regulatory activation at moderate levels and auto-repression at high levels, likely through dimerization, explaining the rising-then-falling temporal expression profile. The double-negative gate (pmar1/hesC) controls alx1 spatially through defined HesC binding sites in the cis-regulatory module. Cis-regulatory reporter assays, mutational analysis of binding sites, synthetic overexpression experiment Developmental Biology High 21723273
2010 Pbx1 and Emx2 bind specific DNA sequences as heterodimers and cooperatively activate Alx1 transcription via a conserved sequence upstream of Alx1, as demonstrated by in vivo ChIP in mouse embryos. Alx1 expression is absent in Pbx1;Emx2 compound mutants, placing Pbx1 and Emx2 upstream of Alx1 in the genetic pathway controlling scapula development. Compound mutant analysis, ChIP (in vivo binding), heterodimer DNA-binding assay, genetic epistasis Development High 20627960
2013 ALX1 promotes epithelial-to-mesenchymal transition (EMT) in ovarian cancer cells by transcriptionally upregulating the EMT regulator Snail (SNAI1). siRNA-mediated knockdown of ALX1 restored E-cadherin expression and suppressed invasion; enforced ALX1 expression induced EMT. Knockdown of Snail blocked EMT activation and invasion caused by ALX1, placing Snail downstream of ALX1. siRNA screen, RNA interference, overexpression, epistasis (Snail knockdown rescue), cell invasion assay Cancer Research Medium 23288509
2012 Morpholino knockdown of zebrafish alx1 demonstrated that Alx1 plays a crucial role in regulating the migration of cranial neural crest (CNC) cells into the frontonasal primordia, coincident with aberrant expression of foxd3 and sox10. This function is specific to Alx1 among Alx family members. Morpholino knockdown, in situ hybridization for neural crest markers (foxd3, sox10), craniofacial phenotypic analysis Human Molecular Genetics Medium 23059813
2019 Genome-wide ChIP-seq in sea urchin embryos identified Alx1-binding sites and direct gene targets, showing that Alx1 directly regulates many terminal differentiation genes and all intermediate transcription factors previously known to be downstream of Alx1. Alx1 binds both palindromic and half-sites in vivo. Testing of 23 high-confidence ChIP-seq peaks identified 18 active cis-regulatory modules; a conserved palindromic Alx1-binding site in one representative CRM was shown to be essential for expression. ChIP-seq, GFP reporter assays, cis-regulatory module analysis, mutagenesis of binding sites Development High 31331943
2021 In vitro and transgenic analyses showed that Alx1 forms dimeric complexes on TAAT-containing half sites by a mechanism distinct from dimerization on palindromic sites. The D2 domain (a 41-amino-acid motif unique to Alx1 acquired via exonization) influences the DNA-binding properties of Alx1 in vitro, and transgenic reporter assays demonstrated that two partially redundant half sites are essential for the PMC-specific activity of the Sp-mtmmpb cis-regulatory module in vivo. In vitro DNA-binding assay, transgenic reporter assay, domain deletion/mutagenesis, ChIP-seq comparison Journal of Biological Chemistry High 34157281
2020 A pathogenic missense variant p.L165F in the homeodomain of ALX1 caused neural crest cells (NCCs) derived from patient iPSCs to show increased apoptosis, elevated progenitor-state markers, and impaired migration. In vivo zebrafish lineage tracing confirmed defective migration of the anterior NCC stream. The migration defect was rescued by soluble BMP2 supplementation or BMP9 antagonist treatment, implicating altered BMP signaling (low BMP2, high BMP9) as a downstream mechanism. iPSC differentiation to NCCs, apoptosis assay, migration assay, zebrafish lineage tracing, BMP protein measurements in culture media, BMP rescue experiments EMBO Molecular Medicine High 32914578
2022 In Alx1 knockout mice generated by CRISPR/Cas9, Alx1 is strongly expressed in frontonasal neural crest cells. Loss of Alx1 caused increased apoptosis of periocular mesenchyme, decreased expression of ocular developmental regulators Pitx2 and Lmxb1 in the periocular mesenchyme, defective optic stalk morphogenesis, and disruption of frontonasal mesenchyme identity (loss of Pax7, ectopic Lhx6/Lhx8 in lateral nasal processes). ALX4 partly complements ALX1 function in frontonasal mesenchyme patterning. CRISPR/Cas9 knockout, in situ hybridization, apoptosis assay, marker gene expression analysis Frontiers in Cell and Developmental Biology High 35127681
2022 ALX1 transcriptionally activates lncRNA AC132217.4, which in turn binds IGF2 mRNA to regulate its expression and downstream AKT activation, controlling osteoblast maturation. ChIP or promoter analysis identified ALX1 as the transcription factor activating AC132217.4 expression during osteogenic differentiation of bone marrow mesenchymal stem cells. Promoter/transcription factor analysis, gain- and loss-of-function experiments, RNA pulldown (lncRNA-mRNA binding), AKT phosphorylation assay Cellular and Molecular Life Sciences Low 35639207
2025 ChIP-seq for H3K27ac combined with RNA-seq identified Alx1 as a direct transcriptional target of retinoic acid (RA) signaling in perioptic mesenchyme, with an RA response element (RARE) near the RA-regulated H3K27ac mark upstream of Alx1. CRISPR/Cas9 knockout of Alx1 in mice caused a defect in optic cup formation due to failure of perioptic mesenchyme to migrate and separate the optic cup from the forebrain neuroepithelium. ChIP-seq (H3K27ac), RNA-seq, in situ hybridization, CRISPR/Cas9 knockout, RARE identification Genes High 41010016
2026 Alx1 is transiently expressed in embryonic cranial mesoderm (not only neural crest cells), and cranial mesoderm-specific inactivation of Alx1 in mice resulted in complete agenesis of extraocular muscles (EOMs) without affecting other muscles. Loss of Alx1 caused failure to activate the core myogenic regulatory network specifically in EOM progenitor cells and increased apoptosis of these progenitors. Temporally induced inactivation showed that Alx1 function is required before, but not after, EOM primordium formation. Conditional/temporally induced CRISPR/Cas9 knockout, lineage-specific inactivation, in situ hybridization, apoptosis assay, myogenic marker analysis Disease Models & Mechanisms High 41670220

Source papers

Stage 0 corpus · 26 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 Alx1, a member of the Cart1/Alx3/Alx4 subfamily of Paired-class homeodomain proteins, is an essential component of the gene network controlling skeletogenic fate specification in the sea urchin embryo. Development (Cambridge, England) 146 12756175
2010 Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. American journal of human genetics 108 20451171
2013 ALX1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. Cancer research 61 23288509
2010 Scapula development is governed by genetic interactions of Pbx1 with its family members and with Emx2 via their cooperative control of Alx1. Development (Cambridge, England) 53 20627960
2012 Defective neural crest migration revealed by a Zebrafish model of Alx1-related frontonasal dysplasia. Human molecular genetics 48 23059813
2015 Aristaless-Like Homeobox protein 1 (ALX1) variant associated with craniofacial structure and frontonasal dysplasia in Burmese cats. Developmental biology 31 26610632
2011 Precise cis-regulatory control of spatial and temporal expression of the alx-1 gene in the skeletogenic lineage of s. purpuratus. Developmental biology 31 21723273
2016 Experimental Approach Reveals the Role of alx1 in the Evolution of the Echinoderm Larval Skeleton. PloS one 27 26866800
2022 Alx1 Deficient Mice Recapitulate Craniofacial Phenotype and Reveal Developmental Basis of ALX1-Related Frontonasal Dysplasia. Frontiers in cell and developmental biology 25 35127681
2020 ALX1-related frontonasal dysplasia results from defective neural crest cell development and migration. EMBO molecular medicine 25 32914578
2019 Genome-wide identification of binding sites and gene targets of Alx1, a pivotal regulator of echinoderm skeletogenesis. Development (Cambridge, England) 22 31331943
2022 ALX1-transcribed LncRNA AC132217.4 promotes osteogenesis and bone healing via IGF-AKT signaling in mesenchymal stem cells. Cellular and molecular life sciences : CMLS 19 35639207
2015 ALX1 promotes migration and invasion of lung cancer cells through increasing snail expression. International journal of clinical and experimental pathology 12 26722397
2016 Exome sequencing revealed a novel splice site variant in the ALX1 gene underlying frontonasal dysplasia. Clinical genetics 10 27324866
2015 Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 8 25736924
2022 Zebrafish models of alx-linked frontonasal dysplasia reveal a role for Alx1 and Alx3 in the anterior segment and vasculature of the developing eye. Biology open 6 35142342
2021 Promoter Methylation-mediated Silencing of the MiR-192-5p Promotes Endometrial Cancer Progression by Targeting ALX1. International journal of medical sciences 6 34104082
2021 Analysis of the DNA-binding properties of Alx1, an evolutionarily conserved regulator of skeletogenesis in echinoderms. The Journal of biological chemistry 6 34157281
2021 Lessons from a transcription factor: Alx1 provides insights into gene regulatory networks, cellular reprogramming, and cell type evolution. Current topics in developmental biology 4 35152981
2003 ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84). Drugs in R&D 2 12848587
2026 The ALX1 transcription factor acts in the early cranial mesoderm to specify extraocular muscle formation. Disease models & mechanisms 1 41670220
2026 lnc-ALX1-2:10 is a novel regulator that enhances proliferation, migration and invasion in prostate cancer cells. Scientific reports 0 41775788
2026 Cmp7-dependent recruitment of Alx1 to a mitotic nuclear envelope hole in Schizosaccharomyces pombe. microPublication biology 0 42136729
2025 Retinoic acid-regulated epigenetic marks identify Alx1 as a direct target gene required for optic cup formation. bioRxiv : the preprint server for biology 0 40667096
2025 Retinoic Acid-Regulated Epigenetic Marks Identify Alx1 as a Direct Target Gene Required for Optic Cup Formation. Genes 0 41010016
2021 Generation of a homozygous ALX1 knockout human embryonic stem cell line (WAe001-A-060) by a CRISPR/Cas9 system. Stem cell research 0 33799274

Missed literature

Know a paper Affinage missed for ALX1? Flag it for the maintainers and the community.

No submissions yet.